Ensysce Biosciences, Inc.
ENSC
$1.59
$0.031.60%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -115.13% | 10.91% | 45.42% | -638.59% | 133.64% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -100.00% |
| Total Other Non-Cash Items | -60.74% | 353.79% | 15.90% | 158.38% | -8.87% |
| Change in Net Operating Assets | 244.03% | -770.08% | -93.36% | 261.85% | -337.85% |
| Cash from Operations | 31.06% | -58.54% | -123.45% | 25.11% | 55.83% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -65.98% | 48.94% | 50.99% | -34.87% | -39.45% |
| Issuance of Common Stock | 3,389.28% | -97.04% | 304.58% | -78.57% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.29% | 1,391.75% | 4.03% | -105.88% | -- |
| Cash from Financing | -22.21% | 48.35% | 1,017.05% | -97.27% | 8,167.77% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 35.97% | -87.03% | 30.99% | -120.95% | 231.74% |